New Insulins: Opportunities in the Treatment of Type 1 Diabetes

• Autor(a) principal: Cabral, Ana Cristina Gaspar
• Data de Publicação: 2021
• Outros Autores: Semedo, Maria, Lavrador, Mariana Aveiro, Lavrador, Marta, Castel-Branco, Margarida, Figueiredo, Isabel Vitória
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.25756/rpf.v13i1.265

Type 1 diabetes (T1D) is one of the focuses of scientific research worldwide. Particularities such as its incidence in the younger population, its multifactorial character and the possibility of giving these patients a quality of life and an average life expectancy equal to that of a healthy individual have led to a great investment in research in this area. Since the therapeutic approach of this disease is based on the use of insulin, the progress in the development of new molecules is remarkable. Currently available are new insulins of ultra-fast and ultra-prolonged action, which have revolutionized the treatment of T1D, namely by allowing the mimicking of physiological insulin secretion and thus increasing the effectiveness and safety of therapy. These new insulins have administration and action profiles more adapted and flexible to the diabetic’s day-to-day life, which allows for the optimization of the therapeutic outcome.